Industry, patient groups weigh in on Trump’s drug pricing plan

Published



The drug industry’s main lobbying arm has proposed limiting how much drug middlemen can pocket for selling medicines, a position it is calling a “bold new stance.”

The middlemen, known as pharmacy benefit managers, have taken heat from the Trump administration for their purported role in high prices that patients pay for medications. Pharmacy benefit managers negotiate drug prices for health insurance companies, but have been accused of not passing on savings from rebates to patients.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.